Over the last few years, several groups have documented that in vivo measurement of D 2 receptors is affected by changes in the concentration of endogenous dopamine. For example, increasing synaptic dopamine concentration with amphetamine or methylphenidate acutely reduced the striatal specific binding of several positron emission tomography (PET) and single photon emission computerized tomography (SPECT) radiotracers in baboons (Logan et al. 1991; Innis et al. 1992; Dewey et al. 1993; Kessler et al. 1993; Laruelle et al. 1997 ) and in humans (Farde et al. 1992; Volkow et al. 1994; Laruelle et al. 1995) . These observations opened the possibility to use PET or SPECT neuroreceptor imaging to gain information about changes in neurotransmitter concentration in the "synaptic space," or more exactly, in the vicinity of the receptors, since not all D 2 receptors are located at synaptic junctions (Yung et al. 1995) . Specifically, the amphetamine or methylphenidate challenges coupled with D 2 receptor imaging provide assessments of relative increase in dopamine release. Using this technique, we recently reported an increase in amphetamine-induced elevation of synaptic dopamine in drug-free patients with schizophrenia compared to controls (Laruelle et al. 1996a ). However, these challenges do not allow measurement of dopamine con-centration at baseline (i.e., in the absence of pharmacological intervention).
In contrast, a pharmacological intervention that would induce a rapid and complete depletion of synaptic dopamine could theoretically provide a measure of D 2 receptor occupancy by dopamine at baseline and, providing knowledge of the in vivo affinity of dopamine for D 2 receptors, an absolute quantification of synaptic dopamine concentration. Preclinical studies indicated that in vivo D 2 receptor occupancy by dopamine is far from negligible. Acute dopamine depletion induced a 10 to 60% increase in the in vivo binding of D 2 receptor radioligands in rodents ( Van der Werf et al. 1986 ; Ross and Jackson 1989b ; Ross and Jackson 1989a; Seeman et al. 1990; Ross 1991; Young et al. 1991) . In baboons, we observed a 30% increase in the specific binding of the D 2 receptor radiotracer [ 
]IBZM) following acute exposure to the tyrosine hydroxylase inhibitor alpha-methyl-para-tyrosine (AMPT) (Laruelle et al. 1997) .
The purpose of the present investigation was to estimate D 2 receptor occupancy by dopamine in the resting state in young healthy volunteers. For each subject, we compared [ 123 I]IBZM binding potential (BP) at baseline and during dopamine depletion as achieved by oral administration of AMPT (1 g every six hours for two days). AMPT is a competitive and reversible inhibitor of tyrosine hydroxylase, the rate limiting enzyme for dopamine and norepinephrine synthesis (Spector et al 1965; Udenfriend et al. 1965) . We selected AMPT as the depleting agent because this drug is approved for human use and because, in contrast to reserpine, AMPT effects are rapidly reversible. The dose and frequency of AMPT administration was selected to provide and maintain significant inhibition of tyrosine hydroxylase activity (Engelman et al. 1968) . AMPT was given for two days, based on the expectation that this duration of treatment would be adequate to produce marked dopamine depletion but too short to induce significant D 2 receptor upregulation. To verify that this regimen does not affect D 2 receptor density, rats were treated with either saline or AMPT for two days and in vitro D 2 receptor density was compared between the two groups.
To minimize delay between scan 1 (baseline state) and scan 2 (depleted state), AMPT treatment was initiated at the end of scan 1, and scan 2 was performed two days after scan 1. Plasma levels of AMPT were measured on each subject on the day of the second scan. Plasma levels of the dopamine metabolite homovanillic acid (HVA) and norepinephrine metabolite 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) were measured at the time of each scan, to assess the effect of AMPT on these metabolites. Clinical ratings were obtained each day of the study to document subjective and motor side effects of AMPT administration.
MATERIALS AND METHODS

Human Subjects
The study was approved by Yale Institutional Review Board for human investigation. Eleven healthy volunteers participated in this study (males, age 25 Ϯ 4 years, with these and subsequent values given as mean Ϯ SD). All subjects gave written informed consent after complete explanation of the risks and possible consequences of the study. The absence of medical, neurological and psychiatric history (including alcohol and drug abuse) was assessed by history, review of systems, physical examination, routine blood tests, urine toxicology and EKG.
Depletion Regimen and Clinical Monitoring
The study lasted four days. Each subject was scanned twice, at 48-hour interval, in the baseline state (scan 1, day 1) and after dopamine depletion (scan 2, day 3). Dopamine depletion was induced by oral administration of AMPT, 1 g every six hours for 48 hours. The first AMPT dose was given on day 1, at the end of scan 1 (8 PM ). On day 2, 1 g AMPT was administered at 6 AM , noon, 6 PM , and midnight. On day 3, 1 g AMPT was given at 6 AM , noon, and just prior the beginning of the second scanning session (5-6 PM ). To prevent the formation of AMPT crystals in the urine, subjects were instructed to drink at least 3 liters of fluids per day, starting the day before the study (Engelman et al. 1968; Lang and Marsden 1982) .
Clinical status of the subjects was evaluated daily at 10 AM from day 1 to day 4. Five subjective feelings, known to be affected by monoamine depletion, were rated by the subjects on a visual analog scale ranging from 1 ("not at all") to 10 ("most ever"): sleepiness, happiness, anxiety, energy and restlessness. Subjects were also evaluated for the presence of extrapyramidal side effects with the Simpson Angus scale (Simpson and Angus 1970) . Urine samples were collected daily and examined for the presence of AMPT crystals. ]iodide in 0.1 M NaOH (no-carrier-added, radionuclidic purity Ͼ 99.8%) as previously described (Kung and Kung 1990 
Radioiodination
Scan Protocol
The previously described radiotracer constant infusion technique was used to perform the experiments under sustained equilibrium binding conditions (Laruelle et al. 1994 (Laruelle et al. , 1995 (Laruelle et al. 1995) . The relatively long time interval needed to achieve equilibrium in all subjects ( Ͼ 150 minutes) is due to limitation in tracer delivery to the brain and diffusional barriers inside the brain (see full discussion in Laruelle et al. 1994) . Each subject received the same dose of [ During the first 210 minutes of the infusion, subjects were allowed to relax in a comfortable setting, in a room adjacent to the camera room. SPECT data were acquired with the three headed PRISM 3000 camera (Picker, Cleveland, Ohio) equipped with high resolution fan beam collimators (resolution at full width halfmaximum, 11 mm; 123 I point source sensitivity, 16.5 counts/sec/ Ci). Continuous scanning was performed during 80 min from 214 Ϯ 13 min to 294 Ϯ 13 min. Ten acquisitions of 8 minutes each were obtained. As opposed to one long acquisition, repeated consecutive acquisitions allowed: 1) correction for shift or drift in head's position; 2) measurement of changes over time in regional activities; 3) measurement of within-experiment standard deviation (noise). Venous plasma samples were obtained every 20 minutes during the imaging session (n ϭ 4) to measure plasma [ 
I]IBZM Plasma Analysis
The plasma was separated by centrifugation for 15 minutes at 3500 rpm and 200 L aliquots were assayed in a calibrated gamma counter to measure concentration of total plasma radioactivity. Plasma (2.5 mL) was extracted three times with 5 mL of ethyl acetate. The combined organic extracts were evaporated to dryness under vacuum, the residue was taken up in 150 L CH 3 OH, diluted with 300 L of water, and analyzed by reversed phase HPLC (C 18 , CH 3 OH/H 2 O/Et 3 N, 80/20/ 0.1, 1 mL/min). Determination of the parent compound fraction was calculated as previously described . Measurement of plasma [ 123 I]IBZM free fraction (f 1 ) was performed in triplicate by ultrafiltration (Centrifree, Amicon, Danvers, MA) as previously described (Gandelman et al. 1994) . To control for between assay variability in f 1 measurement, a standard sample (aliquoted from a pool of plasma obtained from 10 healthy volunteers) was run in parallel in triplicate, and the subject sample f 1 value was corrected using the standard sample. Change over time of the free parent compound was evaluated by linear regression, with the slope expressed as percentage of the average value. Plasma clearance of the parent compound (L/h) was calculated as the ratio of the rate of infusion ( Ci/h) to the total (i.e., free plus plasma protein bound) parent compound plasma concentration at steady state (C ss , Ci/L).
HVA Plasma Analysis
Plasma HVA and MHPG were assayed as previously described by gas chromatography and mass spectrometry, using deuterated internal standards (Maas et al. 1976; Bacopoulos et al. 1978) . The intra-assay and interassay coefficients of variation were 2% and 5%, respectively, for both HVA and MHPG.
AMPT Plasma Analysis
On Day 3, one 5 mL venous blood sample was collected 60 minutes before the last administration of AMPT. AMPT was measured by reverse phase HPLC with fluorescence detection. The procedure used was adapted from that of Anderson et al. (1981) for tyrosine and tryptophan. Sample preparation was similar to that originally used by Engelman et al. (1968) to measure plasma AMPT, except that following protein precipitation we used HPLC to enable separation of AMPT from tyrosine. Following addition of alpha-methyl-metatyrosine as internal standard, equal volumes of serum and 0.7 M HClO 4 were mixed and centrifuged. An aliquot of the protein free filtrate was submitted to chromatography as follows: column, Spherisorb ODS-1; mobile phase, 4% ethanol and 1.5% acetic acid, pH 5.0; flow rate, 2 mL/min; fluorescence detector, excitation 285 nm, emission 317 nm. Standards and controls prepared in serum were carried through the entire procedure and linear squares regression of relative peak height versus concentration was used to fit the standard curve and calculate unknowns. Within run coefficients of variation at 5 and 10 g/mL were 4.5% and 2.4%, respectively. All samples were processed in the same run.
Image Analysis
Count projections were prefiltered using a Wiener 0.5 filter and backprojected using a ramp filter. SPECT images were reoriented to the cantho-meatal line as visualized by the four external fiducial markers. The four slices with highest striatal uptake were summed and attenuation corrected assuming uniform attenuation within an ellipse drawn around the subject's head. For each subject, the same attenuation ellipse was used for scans 1 and 2. Striatal and occipital regions of interest were positioned on the summed images. ) were used to analyze all studies. Right and left striatal regions were averaged. Specific binding was calculated as striatal minus occipital activity. The occipital region was selected as the background region because 1) the density of dopamine D 2 receptors is negligible in this region compared to the striatum (Lidow et al. 1989) ; 2) this region can be identified with greater reliability than the cerebellum; 3) in humans, [ 123 I]IBZM activity in the occipital region is equal to the nonspecific activity in the striatum ). The quality of the equilibrium state was assessed by measuring the change over time of regional activity, expressed relative to the average regional activity.
Outcome Measures
At equilibrium, the [ ), corresponding to the product of the receptor density (B max , nM or pmol per g of brain tissue) and affinity (1/K D , nM Ϫ1 , or mL of plasma per pmol), was thus equal to the B over F ratio. B (Ci per g of brain tissue) was measured as the difference between striatal total activity (STR) and occipital activity (OCC): (Kawai et al. 1991; Laruelle et al. 1994) . Therefore, the intracerebral free [ I]IBZM f 1 C SS measurement during the second experiment.
In the presence of a competitive inhibitor such as endogenous dopamine, equation 1 becomes: ,
where F DA (nM) is the temporal average concentration of free dopamine in the vicinity of receptors, and K I is the inhibition constant of dopamine for [ The percentage occupancy of D 2 receptors by dopamine during scan 1 was calculated as 100*((BP 2 ϪBP 1 )/ BP 2 ). The free synaptic dopamine concentration (F DA ) was obtained by combining and rearranging equations 6 and 7 and defining "a" as the BP 2 /BP 1 ratio, .
Thus F DA can be expressed as a fraction of K I . To calculate the absolute value of F DA , the value of K I must be known. For this calculation, we used the K I value of dopamine for [ 125 I]IBZM binding measured in vitro at room temperature in the presence of sodium ions and antioxidants (160 nM, Brücke et al. 1988) . This model assumes competitive inhibition at one receptor site. In vitro, D 2 receptors present high and low affinity-states for dopamine (Sibley et al. 1982; Hamblin et al. 1984) and since D 2 antagonists have similar affinity for both sites, the interaction between dopamine and D 2 antagonists appears non-competitive under certain conditions Sibley and Creese 1980) . However, the proportion of high-versus low-affinity agonist-binding states of D 2 receptors might be much higher in vivo (90% versus 10%, for the high-and low-affinity states, respectively) than in vitro (50% for each subtype) (Richfield et al. 1986) . The uncertainty about the exact proportion of high-versus low-affinity states of D 2 receptors in vivo precluded incorporating these factors in the model.
Experiment in Rodents
Male Sprague-Dawley rats, 200-250 g, were treated with either AMPT (200 mg/kg) or saline subcutaneous injections twice a day for two days (n ϭ 7 per group). This dose (400 mg/kg per day) was about 7 times the dose used in the human study (4 g per day, or 57 mg/ kg per day in a 70 kg subject). Three hours after the last injection, rats were killed by decapitation. Striatum was immediately dissected on ice and frozen at Ϫ80ЊC. On the day of the assay, samples were homogenized using a Polytron (Kinematica, Kriens-Lu, Switzerland, setting 6 for 10 sec) in 1/40 g of tissue/mL of buffer (50 mM Tris, pH 7.4, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 ). Homogenates were incubated for 10 minutes at 37ЊC and washed three times by centrifugation (20,000g, 4ЊC, 10 min). Incubation was initiated by the successive addition of 100 L [ 125 I]IBZM (final concentration of 5 pM), 100 l buffer or nonradioactive compound (unlabeled IBZM at 0.3 nM or unlabeled raclopride at 1 M, final concentrations) and 800 L of tissue solution (1/1250 g of tissue/mL of buffer, final tissue dilution). Each incubation was performed in quadruplicate (twelve tubes per tissue). Incubation was carried for 45 minutes at 22ЊC and terminated by rapid filtration through GF/B filters on a Cell Harvester (Brandel, Gaithersburg, MD, USA). Filters were rapidly washed three times with 5 mL ice-cold buffer and counted in a COBRA 5010 gamma counter (Packard, Meriden, CT, USA). The nonspecific binding was defined as the binding remaining in the presence of 1 M raclopride. Protein concentration was measured with the method of Lowry et al. (1951) . For each animal, B max and K D were derived by weighted nonlinear regression analysis using the program LIGAND (Munson and Rodbard 1980) . Unlabeled IBZM and raclopride were obtained from Research Biochemicals International, Natick, MA.
Statistical Analyses
All values are provided as mean Ϯ SD. AMPT effects on clinical ratings, plasma catecholamine metabolite, and scan measurements were assessed by repeated measures ANOVA. Correlations were analyzed with simple or multiple linear regression analyses. Significant differences from zero were evaluated by two tailed, one sample t-tests. In vitro B max and K D values were compared between saline and AMPT treated rats with unpaired, two tailed, t-tests. Probability value of 0.05 was used as the significance level.
RESULTS
Clinical Effects of AMPT
One subject could not be scanned in the depleted state (scan 2) because of delayed radioisotope ([ 123 I]NaI) delivery. Another subject was withdrawn from the study because of a side effect of AMPT (diarrhea). Thus, nine out of eleven subjects completed the protocol. AMPT crystals were detected in one subject (day 3 sample). This subject acknowledged poor compliance with fluid intake instructions. AMPT crystals were not present in an additional urine sample collected six hours later, nor in the day 4 sample. Plasma urea and creatinine were measured in this subject on days 3, 4, and 7, and were found unchanged compared to baseline. Thus, no impact of AMPT crystalluria on renal function was observed. AMPT crystalluria was not detected in the other ten subjects.
AMPT effects on clinical ratings were analyzed with repeated measures ANOVA in the nine subjects who completed the protocol. Sleepiness, happiness, restlessness, and Parkinsonism ratings were significantly affected by AMPT treatment (Table 1, Figure 1) . No significant effects of AMPT were noted on anxiety or energy ratings. Sleepiness increased steadily from baseline, peaked on day 3, and resolved on day 4. Happiness significantly decreased from day 1 to day 3, and regained Figure 1 . Effect of AMPT on clinical ratings obtained from day 1 (prior to AMPT administration) to day 4 (16 h after last AMPT dose). Data are presented in change from baseline (day 1) ratings. Sleepiness, restlessness, and mood were selfrated on a 10 points scale from 0 ("not at all") to 10 ("most ever"). Parkinsonism was rated using the Simpson and Angus scale. Error bars were omitted for clarity (see values of SD in Table 1 ). Symptoms presented on the graph showed a significant time effect (Repeated Measure ANOVA, p Ͻ 0.05).
baseline level on day 4. Restlessness increased, and this effect persisted 16 hours after the last AMPT dose (day 4).
Clinical examination revealed mild signs of Parkinsonism in all subjects. These signs were still noted on day 4. Face akinesia, hypo/bradykinesia and resting tremors were the extrapyramidal signs most often noted. Two subjects experienced an acute dystonic reaction (spasms of muscles of the neck and jaw) during the evening of day 3. In one case, this reaction necessitated injection of diphenhydramine 50 mg i.m., with complete and immediate response.
Plasma AMPT
AMPT levels were obtained in 7 out of 9 subjects. The average AMPT plasma concentration was 21 Ϯ 7 g/mL (range 13 to 31 g/mL).
Plasma HVA
AMPT significantly decreased plasma HVA by 70 Ϯ 12% (repeated measures ANOVA, p Ͻ 0.0001, range from 54% to 84%, Table 2 ) and plasma MHPG by 66 Ϯ 6% (p Ͻ 0.0001, range from 57% to 73%). Plasma HVA and MHPG were correlated at baseline (r 2 ϭ 0.65, p ϭ 0.008), but not after AMPT (r 2 Ͻ 0.01, p ϭ 0.98).
SPECT Results
Venous samples for plasma [ The quality of the equilibrium state in the brain was assessed by measuring the change over time of occipital and striatal activities. During scan 1, striatum and occipital activities changed by Ϫ1.7 Ϯ 6.4%/h and ϩ1.1 Ϯ 2.3%/h, respectively. During scan 2, striatal and occipi- Ratings were obtained at 10 AM before (Day 1), during (Day 2 and 3), and after AMPT administration. Subjective ratings (sleepiness, mood, anxiety, energy, and restlessness) were provided by the subjects on a 1 to 10 visual analog scale (1 being "not at all," 10 being "most ever"). Parkinsonism was evaluated by the clinical rater using the Simpson Angus scale.
p is the probability value of repeated measure ANOVA. AMPT was measured on day 3, 60 minutes before the last administration of AMPT. HVA 1 and HVA 2 are plasma HVA concentrations during the scan obtained before and at the end of AMPT administration, respectively. Values for HVA and MHPG are the mean Ϯ SD of 4 independent determinations on 4 plasma samples obtained at 20-minute intervals. Change in HVA was calculated as 100 * (HVA 1 Ϫ HVA 2 )/HVA 1 . tal activities changed by ϩ1.4 Ϯ 4.2%/h and ϩ0.7 Ϯ 2.8%/h, respectively. None of these values were significantly different from zero (one-sample t-tests, p Ͼ 0.05). No effect of AMPT was observed on the slopes of the regional activities (repeated measures ANOVA, striatum: p ϭ 0.28; occipital: p ϭ 0.74). Thus, both scan 1 and 2 were performed under appropriate equilibrium conditions. Table 3 Table 3 ). The average increase was 28 Ϯ 16% (range from 4% to 54%). Comparing the 10 pre-AMPT with the 10 post-AMPT acquisitions, we observed a significant increase in [ 123 I]IBZM BP in 7 out of 9 subjects (Table 2) . Assuming a complete depletion of dopamine following AMPT, these results indicate a baseline D 2 receptor occupancy by dopamine of 21 Ϯ 10%, which would correspond to a synaptic dopamine concentration equal to 0.28 Ϯ 0.16 K I (or 45 Ϯ 25 nM, using a K I value of 160 nM).
AMPT plasma levels on day 3 were not correlated with AMPT-induced change in [ Figure 4A ). This correlation suggested that a relative decrease in plasma HVA could be an indicator of 
Experiment in Rodents
No significant difference was observed in [ 125 I]IBZM K D between saline (0.13 Ϯ 0.04 nM) and AMPT treated rats (0.12 Ϯ 0.02 nM, unpaired t-test, p ϭ 0.40), which suggested that the washing procedure effectively removed dopamine from the preparation in the saline treated rats. No significant difference was observed in D 2 receptor B max between saline (228 Ϯ 63 fmol/mg of protein) and AMPT treated rats (256 Ϯ 28 fmol/mg of protein, unpaired t-test, p ϭ 0.31), which indicated the failure to demonstrate significant D 2 receptor upregulation in the AMPT treated rats.
DISCUSSION
This study showed that AMPT administration (1 g every six h for 2 days) induced a significant increase (ϩ28 Ϯ 16%) in measured [ (Laruelle et al. 1995) , seven subjects were scanned twice at two- ]IBZM BP between test and retest was Ϫ0.1 Ϯ 6.4% (range from Ϫ6.6% to ϩ9.4%). The average absolute difference was 5.6 Ϯ 2%. This reproducibility corresponded to an intraclass coefficient of correlation close to unity (0.96).
The AMPT effect on [ 123 I]IBZM BP suggested that endogenous dopamine occupied at least 20 Ϯ 10% of D 2 receptors in these subjects. Before adopting this conclusion, potential sources of artifactual results must be considered: 1) The increase in [ 123 I]IBZM BP measured after AMPT might have reflected receptor upregulation rather than removal of endogenous dopamine. Yet, in vitro measurement of D 2 receptor density in rodents following 2 days of AMPT administration failed to reveal significant receptor upregulation. This experiment confirmed an earlier study that could not demonstrate significant D 2 receptor upregulation after one week of dopamine depletion induced by 6-hydroxy-dopamine (Narang and Wamsley 1995) . Similarly, acute pretreatment of mice with reserpine (5 mg/kg) resulted in a significant increase in the in vivo specific binding of [ 3 H]raclopride whereas no changes in D 2 receptor density could be detected in vitro (Ross and Jackson, 1989a) . Thus, to the extent that these results can be extrapolated to humans, receptor upregulation does not seem to play a major role in the observed effect. 2) AMPT administration might have increased cerebral blood flow and accelerated the radiotracer delivery to the brain. Yet, [ ]IBZM peripheral clearance, might have affected the quality of equilibrium achieved during scan 2, and such a factor might bias the results of the equilibrium analysis (Carson et al. 1992 ). However, changes over time in striatal and occipital [ 123 I]IBZM activities were minimal (around 1%/h) during both scans 1 and 2, and were not affected by the AMPT administration. This observation indicated that an appropriate state of equilibrium was reached and maintained during the scanning session for both pre-and post-AMPT treatment. Together, these considerations clearly implicate the reduction in endogenous dopamine as the main, if not the only, mechanism responsible for the increase in [ 123 I]IBZM BP. Plasma AMPT levels measured in this study were in good agreement with pharmacokinetic data previously published. Engelman et al. (1968) showed that peak AMPT plasma concentration of 12-14 g/mL were achieved about 2 hours after oral ingestion of a single dose of 1 g AMPT, and that plasma AMPT declined with a half-life of about 4 hours. Therefore, the administration of AMPT every six hours was expected to yield plasma concentrations of about 19-22 g/mL at steadystate. Values observed in this study (21 Ϯ 7 g/mL) were in accordance with this expectation. In this AMPT concentration range, the large variation observed between subjects (10-30 g/mL) would not be expected to have significant consequences for the pharmacodynamic effect of AMPT. Given an average plasma tyrosine level of 10 g/mL, a tyrosine affinity constant for tyrosine hydroxylase of 62.5 M, and an AMPT affinity constant for tyrosine hydroxylase of 17 M , AMPT concentrations of 13 g/mL (smallest value observed in this study), 21 g/ mL (mean value) and 31 g/mL (highest value) are expected to produce about the same degree of enzymatic inhibition (68%, 78% and 83%, respectively, Figure 6 ). The lack of correlation between AMPT plasma levels and the AMPT-induced increase in [ 123 I]IBZM BP is in agreement with this prediction. As pointed out by Engelman et al. (1968) , higher doses of AMPT would not induce significantly more blockade of enzyme, because of the nonlinearity between inhibitor concentration and enzymatic inhibition (Figure 6 ). However, these considerations rest on the assumption that AMPT plasma levels reflect cellular levels, an assumption that has not been validated yet.
To calculate D 2 receptor occupancy by dopamine (21 Ϯ 10%), we assumed that this AMPT regimen induced a complete depletion of synaptic dopamine. This assump- Figure 6 . Relationship between AMPT concentration (g/ mL, x axis) and tyrosine hydroxylase inhibition (%, y axis). This simulation was obtained using a tyrosine concentration of 10 g/mL, and an affinity constant for tyrosine hydroxylase of 17 M for AMPT and 62.5 M for tyrosine . Arrows indicate the percentage inhibition that would correspond to AMPT concentrations of 13, 21 and 31 g/mL, i.e., the lowest, mean, and highest steady state AMPT plasma concentrations in this study. Because of the nonlinearity between percentage inhibition and inhibitor concentration, large differences in AMPT levels observed in this study results in similar inhibition of tyrosine hydroxylase (68%, 78%, and 83% for the lowest, mean, and highest observed AMPT values, respectively). tion might not be valid, since AMPT does not completely block tyrosine hydroxylase. Since dopamine synthesis was not completely blocked, the magnitude of striatal synaptic dopamine depletion achieved by this regimen is uncertain, and the D 2 receptor occupancy by dopamine might be more than 21 Ϯ 10%.
The decrease in plasma HVA might provide an estimate of the decrease in striatal synaptic dopamine. At 4 g per day, AMPT induced cerebrospinal fluid HVA depletion (68 to 77%, Brodie et al. 1971 ) similar to the one measured in the plasma in this study (70 Ϯ 12%). Following AMPT, cerebrospinal fluid HVA depletion reflects striatal dopamine depletion (Mignot and Laude 1985) . These considerations would locate the dopamine depletion achieved in this study in the 70% range. Furthermore, it is often stated that 80% dopamine depletion or 80% D 2 receptor blockade is needed to produce extrapyramidal symptoms (Hornykiewicz and Kish 1987; Farde et al. 1989 ). While our subjects presented extrapyramidal symptoms, the moderate level of these symptoms likewise suggested depletion in the 70 to 80% range.
If we assume for each subject a decrease in striatal dopamine equal to the decrease in plasma HVA (F DA2 / F DA1 ϭ plasma HVA 2 /HVA 1 ), and defining "b" as HVA 2 /HVA 1 , equation 8 becomes:
.
Under this assumption, dopamine occupancy of D 2 receptors would be 29 Ϯ 13% (rather than 21 Ϯ 10%) and baseline dopamine concentration would be 0.45 Ϯ 0.25 K I (rather than 0.28 Ϯ 0.16 K I ). Thus, dopamine occupies at least 20% and possibly as much as 30% of D 2 receptors in vivo in young healthy subjects. These data indicate that endogenous dopamine competition significantly affects in vivo measurement of D 2 receptors with PET or SPECT. To derive absolute synaptic dopamine concentration, we used the published K I value of dopamine for [ 123 I]IBZM binding (160 nM), measured at room temperature (60 min incubation) in the presence of sodium ions and antioxidants (Brücke et al. 1988 ). This seemed a logical choice, given the large range of values of dopamine affinity at D 2 receptors that are reported in the literature (Seeman 1993) . The in vitro measurement of dopamine K D for D 2 receptors is very sensitive to the conditions of the assay and is also affected by the choice of the radiotracer. For example, dopamine has lower affinity for D 2 receptors in the presence than in the absence of sodium ions (Hamblin et al. 1984; Watanabe et al. 1985) and is more potent at competing with (Hall et al. 1990 ). This situation is further complicated by the existence of high and low affinity states of D 2 receptors for dopamine and dopamine agonists in vitro (Sibley et al. 1982) and by the absence of informa-
tion on the proportion of high versus low affinity states in vivo (Richfield et al. 1986 ).
Despite these limitations, our estimates of synaptic dopamine concentration (from 45 Ϯ 25 nM, assuming complete depletion, to 72 Ϯ 40 nM, assuming partial depletion) were very close to values previously measured in rodents using a radiolabelled agonist. Comparing the in vivo binding of the D 2 receptor agonist [ 3 H]N-n-propylnorapomorphine in mouse striatum at baseline and following dopamine depletion induced by ␥-butyrolactone or reserpine, synaptic dopamine concentration in mice striatum was estimated to be in the 40 to 60 nM range (Ross and Jackson 1989b; Ross 1991) , in good agreement with values derived from this study (45 to 72 nM).
When considering these results, the extrasynaptic location of a significant number of D 2 receptors should be kept in mind. As much as 40% of D 2 receptors might be located at nonsynaptic sites (Yung et al. 1995) , where the concentration of dopamine is lower than in the synapse. As a result, synaptic values estimated by in vivo competition studies are likely to underestimate true synaptic dopamine concentration. Using fast-scan voltametry measurement of dopamine release at the synaptic interface, Kawagoe et al. (1992) estimated that the synaptic concentration of dopamine rapidly varies from as high as 200 nM to as low as 6 nM, with a temporal average of about 100 nM. Given the underestimation of synaptic dopamine concentration introduced by the presence of nonsynaptic D 2 receptors, this value is in reasonable agreement with the values derived from receptor competition studies.
Despite the homogeneity of the subjects' demographics (all young males), we observed a large between-subject variability in the AMPT effect (range from 4 to 54%). This variability could relate to differences in the magnitude of AMPT-induced dopamine depletion or to differences in baseline synaptic dopamine concentration. Analysis of variance suggested a significant contribution of both factors. The relationship between plasma HVA depletion and the increase in Studies that would include measurements of AMPT plasma and cerebrospinal fluid levels would be useful to further characterize the sources of the between-subject variability.
In addition to documenting the impact of endogenous dopamine on in vivo D 2 receptors measurement, this study suggests the possibility to use such a paradigm to estimate endogenous dopamine at baseline in the living human brain. Such an application would require the AMPT administration to result in a similar level of tyrosine hydroxylase inhibition across subjects. Alternatively, the relative decrease in plasma HVA could be used to correct for between-subjects variation in AMPT pharmacodynamic effects equation 9. While absolute levels of plasma HVA cannot be readily used as an index of striatal dopamine concentration (for review see Amin et al. 1995) , the relative decrease in plasma HVA induced by AMPT might reflect the degree of tyrosine hydroxylase blockade in both brain and periphery, and might potentially be used to estimate the relative central dopamine depletion. The relationship between AMPT-induced decrease in plasma and cerebrospinal HVA will be further investigated to validate such a method.
In conclusion, this study demonstrates that competition by endogenous dopamine results in a 20 to 30% underestimation of D 2 receptor density in vivo and suggests the possibility to take advantage of this phenomenon to measure striatal synaptic dopamine concentration in humans. With the recently developed ability to measure extrastriatal D 2 receptors (Halldin et al. 1995) , this technique might also allow measurement of dopamine activity in extrastriatal regions, such as the cerebral cortex. Such a method would be very valuable to better understand regional alterations of dopamine activity in schizophrenia and other neuropsychiatric illnesses, and to relate these alterations to the clinical symptomatology.
